{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T12:10:07Z","timestamp":1772453407433,"version":"3.50.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2023AFB670"],"award-info":[{"award-number":["2023AFB670"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CURR MED SCI"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s11596-025-00041-3","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T14:06:46Z","timestamp":1744898806000},"page":"395-404","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Aberrant Sialylation in Ovarian Cancer: Orchestrating Progression, Metastasis, and Therapeutic Hurdles"],"prefix":"10.1007","volume":"45","author":[{"given":"Yu-xin","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang-nian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing-lei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"issue":"3","key":"41_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u2013263.","journal-title":"CA Cancer J Clin."},{"issue":"8","key":"41_CR2","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1002\/ijc.29227","volume":"136","author":"H Zeng","year":"2015","unstructured":"Zeng H, Zheng R, Guo Y, et al. Cancer survival in China, 2003-2005: A population-based study: Cancer survival in China. Int J Cancer. 2015;136(8):1921\u20131930.","journal-title":"Int J Cancer."},{"key":"41_CR3","doi-asserted-by":"publisher","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","volume":"24","author":"JA Ledermann","year":"2013","unstructured":"Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi24\u2013vi32.","journal-title":"Ann Oncol."},{"issue":"4","key":"41_CR4","doi-asserted-by":"publisher","first-page":"650","DOI":"10.3390\/cells11040650","volume":"11","author":"S Akter","year":"2022","unstructured":"Akter S, Rahman MA, Hasan MN, et al. Recent advances in ovarian cancer: Therapeutic strategies, potential biomarkers, and technological improvements. Cells. 2022;11(4):650.","journal-title":"Cells."},{"issue":"1","key":"41_CR5","doi-asserted-by":"publisher","first-page":"19318","DOI":"10.1038\/s41598-021-98201-7","volume":"11","author":"D Tikhonov","year":"2021","unstructured":"Tikhonov D, Kulikova L, Kopylov AT, et al. Proteomic and molecular dynamic investigations of PTM-induced structural fluctuations in breast and ovarian cancer. Sci Rep. 2021;11(1):19318.","journal-title":"Sci Rep."},{"issue":"5","key":"41_CR6","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.cell.2006.08.019","volume":"126","author":"K Ohtsubo","year":"2006","unstructured":"Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health and disease. Cell. 2006;126(5):855\u2013867.","journal-title":"Cell."},{"issue":"6","key":"41_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s00281-024-01025-6","volume":"46","author":"G Wolters-Eisfeld","year":"2024","unstructured":"Wolters-Eisfeld G, Oliveira-Ferrer L. Glycan diversity in ovarian cancer: Unraveling the immune interplay and therapeutic prospects. Semin Immunopathol. 2024;46(6):16.","journal-title":"Semin Immunopathol."},{"issue":"5","key":"41_CR8","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.biocel.2008.10.001","volume":"41","author":"KB Luther","year":"2009","unstructured":"Luther KB, Haltiwanger RS. Role of unusual O-glycans in intercellular signaling. Int J Biochem Cell Biol. 2009;41(5):1011\u20131024.","journal-title":"Int J Biochem Cell Biol."},{"issue":"9","key":"41_CR9","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nrc3982","volume":"15","author":"SS Pinho","year":"2015","unstructured":"Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15(9):540\u2013555.","journal-title":"Nat Rev Cancer."},{"issue":"3","key":"41_CR10","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s12253-015-0033-6","volume":"22","author":"BN Vajaria","year":"2016","unstructured":"Vajaria BN, Patel KR, Begum R, et al. Sialylation: An avenue to target cancer cells. Pathol Oncol Res. 2016;22(3):443\u2013447.","journal-title":"Pathol Oncol Res."},{"issue":"8","key":"41_CR11","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1007\/s13238-018-0597-5","volume":"10","author":"F Li","year":"2019","unstructured":"Li F, Ding J. Sialylation is involved in cell fate decision during development, reprogramming and cancer progression. Protein Cell. 2019;10(8):550\u2013565.","journal-title":"Protein Cell."},{"issue":"8","key":"41_CR12","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.molmed.2008.06.002","volume":"14","author":"A Varki","year":"2008","unstructured":"Varki A. Sialic acids in human health and disease. Trends Mol Med. 2008;14(8):351\u2013360.","journal-title":"Trends Mol Med."},{"issue":"1","key":"41_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41416-020-01126-7","volume":"124","author":"C Dobie","year":"2021","unstructured":"Dobie C, Skropeta D. Insights into the role of sialylation in cancer progression and metastasis. Br J Cancer. 2021;124(1):76\u201390.","journal-title":"Br J Cancer."},{"issue":"2","key":"41_CR14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/med.21407","volume":"37","author":"R Szabo","year":"2017","unstructured":"Szabo R, Skropeta D. Advancement of Sialyltransferase Inhibitors: Therapeutic Challenges and Opportunities. Med Res Rev. 2017;37(2):219\u2013270.","journal-title":"Med Res Rev."},{"issue":"6","key":"41_CR15","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1093\/glycob\/cwq189","volume":"21","author":"M Audry","year":"2011","unstructured":"Audry M, Jeanneau C, Imberty A, et al. Current trends in the structure-activity relationships of sialyltransferases. Glycobiology. 2011;21(6):716\u2013726.","journal-title":"Glycobiology."},{"issue":"8\u20139","key":"41_CR16","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10719-012-9394-1","volume":"29","author":"T Miyagi","year":"2012","unstructured":"Miyagi T, Takahashi K, Hata K, et al. Sialidase significance for cancer progression. Glycoconjugate J. 2012;29(8\u20139):567\u2013577.","journal-title":"Glycoconjugate J."},{"issue":"5","key":"41_CR17","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1074\/jbc.M117.801480","volume":"293","author":"AT Holdbrooks","year":"2018","unstructured":"Holdbrooks AT, Britain CM, Bellis SL. ST6Gal-I sialyltransferase promotes tumor necrosis factor (TNF)-mediated cancer cell survival via sialylation of the TNF receptor 1 (TNFR1) death receptor. J Biol Chem. 2018;293(5):1610\u20131622.","journal-title":"J Biol Chem."},{"issue":"26","key":"41_CR18","doi-asserted-by":"publisher","first-page":"22982","DOI":"10.1074\/jbc.M110.211375","volume":"286","author":"AF Swindall","year":"2011","unstructured":"Swindall AF, Bellis SL. Sialylation of the fas death receptor by ST6Gal-I provides protection against fas-mediated apoptosis in colon carcinoma cells. J Biol Chem. 2011;286(26):22982\u201322990.","journal-title":"J Biol Chem."},{"key":"41_CR19","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.3389\/fimmu.2019.02120","volume":"10","author":"H L\u00e4ubli","year":"2019","unstructured":"L\u00e4ubli H, Borsig L. Altered cell adhesion and glycosylation promote cancer immune suppression and metastasis. Front Immunol. 2019;10:2120.","journal-title":"Front Immunol."},{"issue":"3","key":"41_CR20","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3390\/ijms17030275","volume":"17","author":"J Munkley","year":"2016","unstructured":"Munkley J. The role of sialyl-tn in cancer. Int J Mol Sci. 2016;17(3):275.","journal-title":"Int J Mol Sci."},{"issue":"6","key":"41_CR21","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1074\/jbc.M511826200","volume":"281","author":"R Sewell","year":"2006","unstructured":"Sewell R, B\u00e4ckstr\u00f6m M, Dalziel M, et al. The ST6GalNAc-I sialyltransferase localizes throughout the golgi and is responsible for the synthesis of the tumor-associated sialyl-tn O-glycan in human breast cancer. J Biol Chem. 2006;281(6):3586\u20133594.","journal-title":"J Biol Chem."},{"issue":"1","key":"41_CR22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13048-024-01397-1","volume":"17","author":"L Al-Alem","year":"2024","unstructured":"Al-Alem L, Prendergast JM, Clark J, et al. Sialyl-Tn serves as a potential therapeutic target for ovarian cancer. J Ovarian Res. 2024;17(1):71.","journal-title":"J Ovarian Res."},{"issue":"10","key":"41_CR23","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1080\/14728222.2019.1667977","volume":"23","author":"A B\u00e4renwaldt","year":"2019","unstructured":"B\u00e4renwaldt A, L\u00e4ubli H. The sialoglycan-Siglec glyco-immune checkpoint\u2014a target for improving innate and adaptive anti-cancer immunity. Expert Opin Ther Targets. 2019;23(10):839\u2013853.","journal-title":"Expert Opin Ther Targets."},{"issue":"4","key":"41_CR24","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.it.2020.02.001","volume":"41","author":"S Van De Wall","year":"2020","unstructured":"Van De Wall S, Santegoets KCM, Van Houtum EJH, et al. Sialoglycans and siglecs can shape the tumor immune microenvironment. Trends Immunol. 2020;41(4):274\u2013285.","journal-title":"Trends Immunol."},{"key":"41_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2022.101112","volume":"90","author":"MA Stanczak","year":"2023","unstructured":"Stanczak MA, L\u00e4ubli H. Siglec receptors as new immune checkpoints in cancer. Mol Aspects Med. 2023;90:101112.","journal-title":"Mol Aspects Med."},{"issue":"3","key":"41_CR26","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ygyno.2005.07.016","volume":"99","author":"P Wang","year":"2005","unstructured":"Wang P, Lee W, Juang C, et al. Altered mRNA expressions of sialyltransferases in ovarian cancers. Gynecol Oncol. 2005;99(3):631\u2013639.","journal-title":"Gynecol Oncol."},{"issue":"13","key":"41_CR27","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1158\/0008-5472.CAN-22-3260","volume":"83","author":"K Cao","year":"2023","unstructured":"Cao K, Zhang G, Yang M, et al. Attenuation of sialylation augments antitumor immunity and improves response to immunotherapy in ovarian cancer. Cancer Res. 2023;83(13):2171\u20132186.","journal-title":"Cancer Res."},{"issue":"13","key":"41_CR28","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1158\/0008-5472.CAN-15-2834","volume":"76","author":"MJ Schultz","year":"2016","unstructured":"Schultz MJ, Holdbrooks AT, Chakraborty A, et al. The tumor-associated glycosyltransferase ST6Gal-I regulates stem cell transcription factors and confers a cancer stem cell phenotype. Cancer Res. 2016;76(13):3978\u20133988.","journal-title":"Cancer Res."},{"issue":"1","key":"41_CR29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41420-020-00391-y","volume":"7","author":"EM Satyavarapu","year":"2021","unstructured":"Satyavarapu EM, Nath S, Mandal C. Desialylation of Atg5 by sialidase (Neu2) enhances autophagosome formation to induce anchorage-dependent cell death in ovarian cancer cells. Cell Death Dis. 2021;7(1):26.","journal-title":"Cell Death Dis."},{"issue":"3","key":"41_CR30","first-page":"1449","volume":"21","author":"L Ou","year":"2020","unstructured":"Ou L, He X, Liu N, et al. Sialylation of FGFR1 by ST6Gal\u2011I overexpression contributes to ovarian cancer cell migration and chemoresistance. Mol Med Rep. 2020;21(3):1449\u20131460.","journal-title":"Mol Med Rep."},{"issue":"5","key":"41_CR31","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/cancers9050052","volume":"9","author":"P Wee","year":"2017","unstructured":"Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers. 2017;9(5):52.","journal-title":"Cancers."},{"issue":"10","key":"41_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.105217","volume":"299","author":"KE Ankenbauer","year":"2023","unstructured":"Ankenbauer KE, Rao TC, Mattheyses AL, et al. Sialylation of EGFR by ST6GAL1 induces receptor activation and modulates trafficking dynamics. J Biol Chem. 2023;299(10):105217.","journal-title":"J Biol Chem."},{"issue":"17","key":"41_CR33","doi-asserted-by":"publisher","first-page":"29013","DOI":"10.18632\/oncotarget.15994","volume":"8","author":"K-C Wen","year":"2017","unstructured":"Wen K-C, Sung P-L, Hsieh S-L, et al. \u03b12,3-sialyltransferase type I regulates migration and peritoneal dissemination of ovarian cancer cells. Oncotarget. 2017;8(17):29013\u201329027.","journal-title":"Oncotarget."},{"issue":"1","key":"41_CR34","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13048-018-0385-0","volume":"11","author":"CM Britain","year":"2018","unstructured":"Britain CM, Holdbrooks AT, Anderson JC, et al. Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death. J Ovarian Res. 2018;11(1):12.","journal-title":"J Ovarian Res."},{"issue":"49","key":"41_CR35","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1038\/s41388-024-03187-x","volume":"43","author":"J Shi","year":"2024","unstructured":"Shi J, Zhou R, Wang S, et al. NEU4-mediated desialylation enhances the activation of the oncogenic receptors for the dissemination of ovarian carcinoma. Oncogene. 2024;43(49):3556\u20133569.","journal-title":"Oncogene."},{"issue":"4","key":"41_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.101726","volume":"298","author":"TC Rao","year":"2022","unstructured":"Rao TC, Beggs RR, Ankenbauer KE, et al. ST6Gal-I\u2013mediated sialylation of the epidermal growth factor receptor modulates cell mechanics and enhances invasion. J Biol Chem. 2022;298(4):101726.","journal-title":"J Biol Chem."},{"issue":"6","key":"41_CR37","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.devcel.2008.05.009","volume":"14","author":"J Yang","year":"2008","unstructured":"Yang J, Weinberg RA. Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev Cell. 2008;14(6):818\u2013829.","journal-title":"Dev Cell."},{"issue":"11","key":"41_CR38","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/s41419-018-1101-0","volume":"9","author":"X Wu","year":"2018","unstructured":"Wu X, Zhao J, Ruan Y, et al. Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-\u03b21-induced EMT and confers paclitaxel resistance in ovarian cancer. Cell Death Dis. 2018;9(11):1102.","journal-title":"Cell Death Dis."},{"issue":"8","key":"41_CR39","doi-asserted-by":"publisher","first-page":"314","DOI":"10.2183\/pjab.85.314","volume":"85","author":"K Miyazono","year":"2009","unstructured":"Miyazono K. Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer. Proc Jpn Acad Ser B Phys Biol Sci. 2009;85(8):314\u2013323.","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci."},{"issue":"3","key":"41_CR40","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","volume":"177","author":"E Lengyel","year":"2010","unstructured":"Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010;177(3):1053\u20131064.","journal-title":"Am J Pathol."},{"issue":"8","key":"41_CR41","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.3390\/cancers11081044","volume":"11","author":"N Thomakos","year":"2019","unstructured":"Thomakos N, Diakosavvas M, Machairiotis N, et al. Rare distant metastatic disease of ovarian and peritoneal carcinomatosis: A review of the literature. Cancers. 2019;11(8):1044.","journal-title":"Cancers."},{"issue":"1","key":"41_CR42","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1757-2215-1-3","volume":"1","author":"DR Christie","year":"2008","unstructured":"Christie DR, Shaikh FM, Lucas JA, et al. ST6Gal-I expression in ovarian cancer cells promotes an invasive phenotype by altering integrin glycosylation and function. J Ovarian Res. 2008;1(1):3.","journal-title":"J Ovarian Res."},{"issue":"8","key":"41_CR43","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1093\/glycob\/cwad051","volume":"33","author":"RB Jones","year":"2023","unstructured":"Jones RB, Silva AD, Ankenbauer KE, et al. Role of the ST6GAL1 sialyltransferase in regulating ovarian cancer cell metabolism. Glycobiology. 2023;33(8):626\u2013636.","journal-title":"Glycobiology."},{"issue":"2","key":"41_CR44","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.tjog.2018.02.015","volume":"57","author":"P-L Sung","year":"2018","unstructured":"Sung P-L, Wen K-C, Horng H-C, et al. The role of \u03b12,3-linked sialylation on clear cell type epithelial ovarian cancer. Taiwan J Obstet Gynecol. 2018;57(2):255\u2013263.","journal-title":"Taiwan J Obstet Gynecol."},{"key":"41_CR45","doi-asserted-by":"publisher","first-page":"1432333","DOI":"10.3389\/fonc.2024.1432333","volume":"14","author":"A Fox","year":"2024","unstructured":"Fox A, Leonard GD, Adzibolosu N, et al. Adipose microenvironment promotes hypersialylation of ovarian cancer cells. Front Oncol. 2024;14:1432333.","journal-title":"Front Oncol."},{"issue":"19","key":"41_CR46","doi-asserted-by":"publisher","first-page":"5962","DOI":"10.3390\/molecules26195962","volume":"26","author":"Y Tamada","year":"2021","unstructured":"Tamada Y, Nomura H, Aoki D, et al. A possible inhibitory role of sialic acid on MUC1 in peritoneal dissemination of clear cell-type ovarian cancer cells. Molecules. 2021;26(19):5962.","journal-title":"Molecules."},{"issue":"1","key":"41_CR47","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1757-2215-6-25","volume":"6","author":"MJ Schultz","year":"2013","unstructured":"Schultz MJ, Swindall AF, Wright JW, et al. ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells. J Ovarian Res. 2013;6(1):25.","journal-title":"J Ovarian Res."},{"issue":"1\u20132","key":"41_CR48","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11010-009-0147-9","volume":"331","author":"S Huang","year":"2009","unstructured":"Huang S, Day TW, Choi M-R, et al. Human \u03b2-galactoside \u03b1-2,3-sialyltransferase (ST3Gal III) attenuated Taxol-induced apoptosis in ovarian cancer cells by downregulating caspase-8 activity. Mol Cell Biochem. 2009;331(1\u20132):81\u201388.","journal-title":"Mol Cell Biochem."},{"issue":"4","key":"41_CR49","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nri2056","volume":"7","author":"PR Crocker","year":"2007","unstructured":"Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol. 2007;7(4):255\u2013266.","journal-title":"Nat Rev Immunol."},{"issue":"12","key":"41_CR50","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1158\/2326-6066.CIR-22-0366","volume":"10","author":"H L\u00e4ubli","year":"2022","unstructured":"L\u00e4ubli H, Nalle SC, Maslyar D. Targeting the siglec\u2013sialic acid immune axis in cancer: Current and future approaches. Cancer Immunol Res. 2022;10(12):1423\u20131432.","journal-title":"Cancer Immunol Res."},{"issue":"44","key":"41_CR51","doi-asserted-by":"publisher","first-page":"eadh4379","DOI":"10.1126\/sciadv.adh4379","volume":"9","author":"D Bordoloi","year":"2023","unstructured":"Bordoloi D, Kulkarni AJ, Adeniji OS, et al. Siglec-7 glyco-immune binding mAbs or NK cell engager biologics induce potent antitumor immunity against ovarian cancers. Sci Adv. 2023;9(44):eadh4379.","journal-title":"Sci Adv."},{"issue":"31","key":"41_CR52","doi-asserted-by":"publisher","first-page":"28619","DOI":"10.1074\/jbc.M302741200","volume":"278","author":"N Kui Wong","year":"2003","unstructured":"Kui Wong N, Easton RL, Panico M, et al. Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J Biol Chem. 2003;278(31):28619\u201328634.","journal-title":"J Biol Chem."},{"issue":"1","key":"41_CR53","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1476-4598-5-50","volume":"5","author":"JA Gubbels","year":"2006","unstructured":"Gubbels JA, Belisle J, Onda M, et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006;5(1):50.","journal-title":"Mol Cancer."},{"key":"41_CR54","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/1476-4598-9-118","volume":"9","author":"JA Belisle","year":"2010","unstructured":"Belisle JA, Horibata S, Jennifer GAA, et al. Identification of siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Mol Cancer. 2010;9:118.","journal-title":"Mol Cancer."},{"issue":"1","key":"41_CR55","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s13048-023-01207-0","volume":"16","author":"Y Wu","year":"2023","unstructured":"Wu Y, Liu Q, Xie Y, et al. MUC16 stimulates neutrophils to an inflammatory and immunosuppressive phenotype in ovarian cancer. J Ovarian Res. 2023;16(1):181.","journal-title":"J Ovarian Res."},{"issue":"7769","key":"41_CR56","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","volume":"572","author":"AA Barkal","year":"2019","unstructured":"Barkal AA, Brewer RE, Markovic M, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019;572(7769):392\u2013396.","journal-title":"Nature."},{"issue":"1","key":"41_CR57","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s12094-023-03240-3","volume":"26","author":"Q Zheng","year":"2023","unstructured":"Zheng Q, Du X, Zhang J, et al. Delivery of SIRT1 by cancer-associated adipocyte-derived extracellular vesicles regulates immune response and tumorigenesis of ovarian cancer cells. Clin Transl Oncol. 2023;26(1):190\u2013203.","journal-title":"Clin Transl Oncol."},{"issue":"2","key":"41_CR58","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1021\/acs.molpharmaceut.2c00557","volume":"20","author":"C Chen","year":"2023","unstructured":"Chen C, Zhang L, Ruan Z. GATA3 Encapsulated by Tumor-Associated Macrophage-Derived Extracellular Vesicles Promotes Immune Escape and Chemotherapy Resistance of Ovarian Cancer Cells by Upregulating the CD24\/Siglec-10 Axis. Mol Pharmaceutics. 2023;20(2):971\u2013986.","journal-title":"Mol Pharmaceutics."},{"issue":"9","key":"41_CR59","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1093\/glycob\/cwu068","volume":"24","author":"G-Y Chen","year":"2014","unstructured":"Chen G-Y, Brown NK, Zheng P, et al. Siglec-G\/10 in self-nonself discrimination of innate and adaptive immunity. Glycobiology. 2014;24(9):800\u2013806.","journal-title":"Glycobiology."},{"issue":"5","key":"41_CR60","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nbt.1846","volume":"29","author":"G-Y Chen","year":"2011","unstructured":"Chen G-Y, Chen X, King S, et al. Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction. Nat Biotechnol. 2011;29(5):428\u2013435.","journal-title":"Nat Biotechnol."},{"issue":"22","key":"41_CR61","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1182\/blood-2013-12-545335","volume":"123","author":"T Toubai","year":"2014","unstructured":"Toubai T, Hou G, Mathewson N, et al. Siglec-G-CD24 axis controls the severity of graft-versus-host disease in mice. Blood. 2014;123(22):3512\u20133523.","journal-title":"Blood."},{"issue":"9","key":"41_CR62","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007099","volume":"11","author":"Y Wang","year":"2023","unstructured":"Wang Y, He M, Zhang C, et al. Siglec-9+ tumor-associated macrophages delineate an immunosuppressive subset with therapeutic vulnerability in patients with high-grade serous ovarian cancer. J Immunother Cancer. 2023;11(9):e007099.","journal-title":"J Immunother Cancer."},{"issue":"5\u20136","key":"41_CR63","first-page":"389","volume":"20","author":"H Berbe\u0107","year":"1999","unstructured":"Berbe\u0107 H, Paszkowska A, Siwek B, et al. Total serum sialic acid concentration as a supporting marker of malignancy in ovarian neoplasia. Eur J Gynaecol Oncol. 1999;20(5\u20136):389\u2013392.","journal-title":"Eur J Gynaecol Oncol."},{"issue":"1","key":"41_CR64","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1559-0275-9-10","volume":"9","author":"V Shetty","year":"2012","unstructured":"Shetty V, Hafner J, Shah P, et al. Investigation of ovarian cancer associated sialylation changes in N-linked glycopeptides by quantitative proteomics. Clin Proteomics. 2012;9(1):10.","journal-title":"Clin Proteomics."},{"issue":"1","key":"41_CR65","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1200\/JCO.1992.10.1.95","volume":"10","author":"H Kobayashi","year":"1992","unstructured":"Kobayashi H, Terao T, Kawashima Y. Serum sialyl tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer. J Clin Oncol. 1992;10(1):95\u2013101.","journal-title":"J Clin Oncol."},{"issue":"1","key":"41_CR66","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/IGC.0000000000000586","volume":"26","author":"G S\u00f6l\u00e9tormos","year":"2016","unstructured":"S\u00f6l\u00e9tormos G, Duffy MJ, Othman Abu Hassan S, et al. Clinical use of cancer biomarkers in epithelial ovarian cancer: Updated guidelines from the european group on tumor markers. Int J Gynecol Cancer. 2016;26(1):43\u201351.","journal-title":"Int J Gynecol Cancer."},{"issue":"4","key":"41_CR67","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/IGC.0b013e3182473292","volume":"22","author":"K Akita","year":"2012","unstructured":"Akita K, Yoshida S, Ikehara Y, et al. Different Levels of Sialyl-Tn Antigen Expressed on MUC16 in Patients With Endometriosis and Ovarian Cancer: Int J Gynecol Cancer. 2012;22(4):531\u2013538.","journal-title":"Int J Gynecol Cancer."},{"issue":"3","key":"41_CR68","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ygyno.2015.10.012","volume":"139","author":"M Mikami","year":"2015","unstructured":"Mikami M, Tanabe K, Matsuo K, et al. Fully-sialylated alpha-chain of complement 4-binding protein: Diagnostic utility for ovarian clear cell carcinoma. Gynecol Oncol. 2015;139(3):520\u2013528.","journal-title":"Gynecol Oncol."},{"issue":"7","key":"41_CR69","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1021\/pr400169n","volume":"12","author":"J Wu","year":"2013","unstructured":"Wu J, Xie X, Nie S, et al. Altered Expression of Sialylated Glycoproteins in Ovarian Cancer Sera Using Lectin-based ELISA Assay and Quantitative Glycoproteomics Analysis. J Proteome Res. 2013;12(7):3342\u20133352.","journal-title":"J Proteome Res."},{"issue":"6","key":"41_CR70","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1200\/JCO.1991.9.6.983","volume":"9","author":"H Kobayashi","year":"1991","unstructured":"Kobayashi H, Terao T, Kawashima Y. Clinical evaluation of circulating serum sialyl tn antigen levels in patients with epithelial ovarian cancer. J Clin Oncol. 1991;9(6):983\u2013987.","journal-title":"J Clin Oncol."},{"issue":"11","key":"41_CR71","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1093\/glycob\/cwy065","volume":"28","author":"B Wichert","year":"2018","unstructured":"Wichert B, Milde-Langosch K, Galatenko V, et al. Prognostic role of the sialyltransferase ST6GAL1 in ovarian cancer. Glycobiology. 2018;28(11):898\u2013903.","journal-title":"Glycobiology."},{"issue":"12","key":"41_CR72","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/s41589-020-0622-x","volume":"16","author":"MA Gray","year":"2020","unstructured":"Gray MA, Stanczak MA, Mantuano NR, et al. Targeted glycan degradation potentiates the anticancer immune response in vivo. Nat Chem Biol. 2020;16(12):1376\u20131384.","journal-title":"Nat Chem Biol."},{"issue":"1","key":"41_CR73","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1186\/s12967-022-03714-y","volume":"20","author":"J Huang","year":"2022","unstructured":"Huang J, Li M, Mei B, et al. Whole-cell tumor vaccines desialylated to uncover tumor antigenic gal\/GalNAc epitopes elicit anti-tumor immunity. J Transl Med. 2022;20(1):496.","journal-title":"J Transl Med."},{"key":"41_CR74","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.3389\/fimmu.2018.02268","volume":"9","author":"JP Murad","year":"2018","unstructured":"Murad JP, Kozlowska AK, Lee HJ, et al. Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells. Front Immunol. 2018;9:2268.","journal-title":"Front Immunol."}],"container-title":["Current Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-025-00041-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11596-025-00041-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-025-00041-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T08:02:49Z","timestamp":1751875369000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11596-025-00041-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":74,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["41"],"URL":"https:\/\/doi.org\/10.1007\/s11596-025-00041-3","relation":{},"ISSN":["2096-5230","2523-899X"],"issn-type":[{"value":"2096-5230","type":"print"},{"value":"2523-899X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"assertion":[{"value":"29 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}